MarkTomislavOstermanMD
Gastroenterology • Chesterbrook, PAAdvanced Endoscopic Interventional, Inflammatory Bowel Disease
Associate Professor, Medicine, Perelman School of Medicine
Dr. Osterman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
250 King of Prussia Rd
Chesterbrook, PA 19087Phone+1 800-789-7366Fax+1 610-902-1544
Education & Training
University of Pennsylvania Health SystemFellowship, Gastroenterology, 2002 - 2005
Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999
Certifications & Licensure
PA State Medical License 2003 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of Cimzia for the Treatment of Ulcerative Colitis Start of enrollment: 2010 Dec 01
- Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis Start of enrollment: 2012 Feb 01
- Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease Start of enrollment: 2014 Feb 01
Publications & Presentations
PubMed
- 5 citationsENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse.Vipul Jairath, Andres Yarur, Mark T Osterman, Alexandra James, Diane Balma
Clinical Gastroenterology and Hepatology. 2024-05-01 - 14 citationsReal-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory...Niels Vande Casteele, William J Sandborn, Brian G Feagan, Séverine Vermeire, Parambir S Dulai
Alimentary Pharmacology & Therapeutics. 2022-08-01 - 3 citationsAssociation Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel DiseasesAndres Yarur, Parakkal Deepak, Niels Vande Casteele, Robert Battat, Anjali Jain
Digestive Diseases and Sciences. 2021-10-01
Press Mentions
Corrigendum: 2016 ACG Abstracts-Inflammatory Bowel DiseaseJanuary 10th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
